An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Parsabiv

Chemical Nameetelcalcetide
Dosage FormInjection (intravenous; 2.5 mg/0.5 ml, 5 mg/ml, 10 mg/2 ml)
Drug ClassReceptor agonists
SystemEndocrine
CompanyKAI Pharmaceuticals, Inc.
Approval Year2017

Indication

  • To treat secondary hyperparathyroidism in adults with chronic kidney disease on hemodialysis.
Last updated on 10/13/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Parsabiv (Etelcalcetide) Prescribing Information 2017KAI Pharmaceuticals, Inc., Thousand Oaks, CA
Document TitleYearSource
Etelcalcetide for treating secondary hyperparathyroidism. 2017NICE
Document TitleYearSource
Comparative effectiveness of calcimimetic agents for secondary hyperparathyroidism in adults: A systematic review and network meta-analysis. 2020American Journal of Kidney Diseases